251 related articles for article (PubMed ID: 36755094)
1. TET2 guards against unchecked BATF3-induced CAR T cell expansion.
Jain N; Zhao Z; Feucht J; Koche R; Iyer A; Dobrin A; Mansilla-Soto J; Yang J; Zhan Y; Lopez M; Gunset G; Sadelain M
Nature; 2023 Mar; 615(7951):315-322. PubMed ID: 36755094
[TBL] [Abstract][Full Text] [Related]
2. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Fraietta JA; Nobles CL; Sammons MA; Lundh S; Carty SA; Reich TJ; Cogdill AP; Morrissette JJD; DeNizio JE; Reddy S; Hwang Y; Gohil M; Kulikovskaya I; Nazimuddin F; Gupta M; Chen F; Everett JK; Alexander KA; Lin-Shiao E; Gee MH; Liu X; Young RM; Ambrose D; Wang Y; Xu J; Jordan MS; Marcucci KT; Levine BL; Garcia KC; Zhao Y; Kalos M; Porter DL; Kohli RM; Lacey SF; Berger SL; Bushman FD; June CH; Melenhorst JJ
Nature; 2018 Jun; 558(7709):307-312. PubMed ID: 29849141
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
4. TET2, tumor control, and CAR T cell hyperproliferation.
Dash B; Hogan PG
Trends Cancer; 2023 Jul; 9(7):521-523. PubMed ID: 37173187
[TBL] [Abstract][Full Text] [Related]
5. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells.
Collins SM; Alexander KA; Lundh S; Dimitri AJ; Zhang Z; Good CR; Fraietta JA; Berger SL
Sci Adv; 2023 Jul; 9(29):eadh2605. PubMed ID: 37467321
[TBL] [Abstract][Full Text] [Related]
6. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
7. T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy.
Zebley CC; Youngblood B
Trends Immunol; 2023 Jun; 44(6):397-398. PubMed ID: 36959018
[TBL] [Abstract][Full Text] [Related]
8. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.
Weber EW; Parker KR; Sotillo E; Lynn RC; Anbunathan H; Lattin J; Good Z; Belk JA; Daniel B; Klysz D; Malipatlolla M; Xu P; Bashti M; Heitzeneder S; Labanieh L; Vandris P; Majzner RG; Qi Y; Sandor K; Chen LC; Prabhu S; Gentles AJ; Wandless TJ; Satpathy AT; Chang HY; Mackall CL
Science; 2021 Apr; 372(6537):. PubMed ID: 33795428
[TBL] [Abstract][Full Text] [Related]
9. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
10. FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic strategies to boost CAR T cell therapy.
Akbari B; Ghahri-Saremi N; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Mol Ther; 2021 Sep; 29(9):2640-2659. PubMed ID: 34365035
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic Analysis of CAR-T Cells.
de Azevedo JTC; Mizukami A; Moço PD; Malmegrim KCR
Methods Mol Biol; 2020; 2086():195-201. PubMed ID: 31707677
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell persistence and memory cell formation.
McLellan AD; Ali Hosseini Rad SM
Immunol Cell Biol; 2019 Aug; 97(7):664-674. PubMed ID: 31009109
[TBL] [Abstract][Full Text] [Related]
14. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
15. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
16. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
[TBL] [Abstract][Full Text] [Related]
17. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
Tantalo DG; Oliver AJ; von Scheidt B; Harrison AJ; Mueller SN; Kershaw MH; Slaney CY
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035114
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
19. Implications of TET2 in CAR-T Cell Activity and Target Response to CAR-T Cell Therapy: Lessons Learned from T Cells.
Pasca S; Jurj A; Constantinescu C; Zdrenghea M; Tomuleasa C
Crit Rev Immunol; 2021; 41(1):13-21. PubMed ID: 33822522
[TBL] [Abstract][Full Text] [Related]
20. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
